UroToday - The Global Online Community of Urologists
网页Reno, Nevada (UroToday.com) -- Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast …
UroToday - The Global Online Community of Urologists
网页While the data are still maturing, median time to PSA progression is currently at 16.6 months. Read More. UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Bladder Cancer - UroToday
网页Bladder cancer remains the sixth most commonly diagnosed cancer in the United States, with an estimated 82,290 incident cases in 2023. 1 Because of the persistent recurrence risk of NMIBC in a highly comorbid population, there has been an FDA-led drive towards developing novel treatment options for these patients. The following article will highlight …
ASCO 2021 - UroToday
网页ASCO 2021: Safety and Efficacy of AMG 160, a Half-Life Extended BiTE Immune Therapy Targeting PSMA, and Other Therapies for Metastatic Castration-Resistant Prostate Cancer. ASCO 2021: Complementary Detection of Genomic Alterations in Metastatic Castration Resistant Prostate Cancer From CheckMate 9KD Through Analyses of Tumor Tissue …
Prostate Cancer Abstracts and Beyond - UroToday
网页2024年9月11日 · Prostate Cancer. September 9, 2024. Long Noncoding RNA EPCART Regulates Translation Through PI3K/AKT/mTOR Pathway and PDCD4 in Prostate Cancer - Beyond the Abstract. Prostate Cancer. September 4, 2024. Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate …
The Latest Research on Bladder Cancer - UroToday
网页Bladder cancer remains the sixth most commonly diagnosed cancer in the United States, with an estimated 82,290 incident cases in 2023. 1 Because of the persistent recurrence risk of NMIBC in a highly comorbid population, there has been an FDA-led drive towards developing novel treatment options for these patients. The following article will highlight …
2023 Society of Urologic Oncology (SUO) Annual Meeting
网页SUO 2023 Press Releases. SUO 2023 Meeting: New Real World Evidence shows Significant Decrease in Risk of Bladder Cancer Recurrence with Blue Light Cystoscopy. New Data Show Durable Response Following Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg) UroGen will Present Scientific Advances in Bladder Cancer at the …
Bladder Cancer Advances in 2020 and 2021 - UroToday
网页2021年2月3日 · In May 2020, at the virtual ASCO meeting, investigators updated the study results covering a median follow-up time of 28.4 months. 13 The overall rate of complete response (CR) was 41%, with a median duration of response of 16.2 months; in the overall efficacy analysis, 19% of patients who received pembrolizumab had a CR that exceeded …
ASCO GU 2022 Bladder Cancer - UroToday
网页ASCO GU 2022: ABLE: Phase 2, Single-Arm, Two-Stage Study of Nab-Paclitaxel with Anti-PD1/PDL1 in Advanced Urothelial Cancer. ASCO GU 2022: Biomarker Analysis and Updated Clinical Follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of Nivolumab, Gemcitabine, and Cisplatin in Patients with MIBC Undergoing Cystectomy.
EAU 2022 Bladder Cancer - UroToday
网页EAU 2022: First Line Avelumab in PD-L1+ve Metastatic or Locally Advanced Urothelial Cancer (aUC) Patients Unfit for Cisplatin: The ARIES Trial. EAU 2022: Biodegradable Device for Controlled Release of Cisplatin As Local Chemotherapy for Bladder Cancer. EAU 2022: State-of-the-art Lecture Landscape of Current Trials with Intravesical Treatment in ...